These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12796649)

  • 21. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
    Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
    Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy.
    Kuniyasu H; Ukai R; Johnston D; Troncoso P; Fidler IJ; Pettaway CA
    Clin Cancer Res; 2003 Jun; 9(6):2185-94. PubMed ID: 12796385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features.
    Köksal IT; Ozcan F; Kiliçaslan I; Tefekli A
    Pathology; 2002 Jun; 34(3):233-8. PubMed ID: 12109783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
    Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
    J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
    Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
    Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
    Ray ME; Mehra R; Sandler HM; Daignault S; Shah RB
    J Urol; 2006 Oct; 176(4 Pt 1):1409-14; discussion 1414. PubMed ID: 16952645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence.
    Mejean A; Vona G; Nalpas B; Damotte D; Brousse N; Chretien Y; Dufour B; Lacour B; Bréchot C; Paterlini-Bréchot P
    J Urol; 2000 Jun; 163(6):2022-9. PubMed ID: 10799250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy.
    de la Taille A; Buttyan R; Benson MC; Katz AE
    Semin Urol Oncol; 1998 Aug; 16(3):137-44. PubMed ID: 9741418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
    Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
    Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.